Walder Wyss with Enantios on its seed financing round

Walder Wyss advised Enantios, an Eidgenössische Technische Hochschule Zürich (ETH) Zurich deep-tech Spin-off, on the completion of its seed financing round.

The Enantios technology, developed over a five year research project at ETH Zurich, enables the complete characterization of complex molecules and aspects of the three dimensional structure which are not possible to resolve with other methods. The new funds shall be used in particular for technology development and enhancement, talent acquisition and strategic partnership to accelerate its go-to-market.

Privilège Ventures led this funding round with additional capital from Zürcher Kantonalbank and several Family Offices and private investors.

Walder Wyss’ team

The team included corporate/M&A partner Alex Nikitine (pictured), corporate/M&A associate Letizia Schlegel, corporate/M&A counsel Stefan Walder and tax partner Fabienne Limacher.

Enantios

Enantios specializes in advanced molecular characterization, leveraging innovative Raman Optical Activity (ROA) technology to revolutionize the detailed analysis and characterization of complex molecules, particularly in pharmaceutical development